FATE
Fate Therapeutics Inc
$2.99
+0.00 (+0.00%)
At close · Jul 15
Market Cap
$318.21M
Shares
116,559,186
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-06-15 | 2026-06-12 | |
| 8-K | 2026-06-04 | — | |
| 8-K | 2026-05-13 | — | |
| 10-Q | 2026-05-13 | 2026-03-31 | |
| DEF 14A | 2026-04-24 | 2026-06-12 | |
| 8-K | 2026-02-26 | — | |
| 10-K | 2026-02-26 | 2025-12-31 | |
| 10-Q | 2025-11-13 | 2025-09-30 | |
| 8-K | 2025-11-13 | — | |
| 8-K | 2025-10-27 | 2025-10-26 | |
| 8-K | 2025-10-14 | 2025-10-10 | |
| 10-Q | 2025-08-12 | 2025-06-30 | |
| 8-K | 2025-08-12 | 2025-08-07 | |
| 8-K/A | 2025-06-17 | 2025-05-29 | |
| 8-K | 2025-05-30 | 2025-05-29 | |
| 10-Q | 2025-05-13 | 2025-03-31 | |
| 8-K | 2025-05-13 | — | |
| DEF 14A | 2025-04-17 | 2025-05-29 | |
| 8-K | 2025-03-05 | — | |
| 10-K | 2025-03-05 | 2024-12-31 | |
| 8-K | 2025-01-06 | 2024-12-31 | |
| 8-K | 2024-11-29 | 2024-11-27 | |
| 10-Q | 2024-11-12 | 2024-09-30 | |
| 8-K | 2024-11-12 | — | |
| 8-K | 2024-08-30 | 2024-08-26 | |
| 8-K | 2024-08-13 | — | |
| 10-Q | 2024-08-13 | 2024-06-30 | |
| 8-K | 2024-07-31 | 2024-07-29 | |
| 8-K | 2024-06-10 | 2024-06-07 | |
| 8-K | 2024-06-07 | 2024-06-03 | |
| 8-K | 2024-05-31 | 2024-05-30 | |
| 8-K | 2024-05-09 | — | |
| 10-Q | 2024-05-09 | 2024-03-31 | |
| 8-K | 2024-05-09 | — | |
| DEF 14A | 2024-04-26 | 2024-06-07 | |
| 8-K | 2024-03-21 | 2024-03-19 | |
| 10-K | 2024-02-26 | 2023-12-31 | |
| 8-K | 2024-02-26 | — | |
| 8-K | 2023-11-08 | — | |
| 10-Q | 2023-11-08 | 2023-09-30 | |
| 8-K | 2023-11-08 | — | |
| 8-K | 2023-09-01 | 2023-08-30 | |
| 10-Q | 2023-08-08 | 2023-06-30 | |
| 8-K | 2023-08-08 | — | |
| 8-K | 2023-06-09 | 2023-06-06 | |
| 8-K | 2023-06-08 | — | |
| 8-K | 2023-06-07 | — | |
| 8-K | 2023-05-03 | — | |
| 10-Q | 2023-05-03 | 2023-03-31 | |
| DEF 14A | 2023-04-21 | 0001-01-01 |
Showing 1–50 of 98 filings
Key facts
CIK
1434316
CUSIP
31189P102
13F (30d)
10 filings
10 filers
Visit website
Investor relations